Evidence map›Paper›PMID 30361682›Full record

ArticleScientific reports2018

Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML.

Eimear O' Reilly, Sukhraj Pal S Dhami, Denis V Baev, Csaba Ortutay, Anna Halpin-McCormick, Ruth Morrell, Corrado Santocanale, Afshin Samali, John Quinn, Michael E O'Dwyer and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Eimear O' ReillyApoptosis Research Centre, School of Natural Sciences, National University of Ireland Galway, Galway, Ireland.
Sukhraj Pal S DhamiApoptosis Research Centre, School of Natural Sciences, National University of Ireland Galway, Galway, Ireland.
Denis V BaevApoptosis Research Centre, School of Natural Sciences, National University of Ireland Galway, Galway, Ireland.
Csaba OrtutayApoptosis Research Centre, School of Medicine, National University of Ireland Galway, Galway, Ireland.
Anna Halpin-McCormickApoptosis Research Centre, School of Natural Sciences, National University of Ireland Galway, Galway, Ireland.
Ruth MorrellApoptosis Research Centre, School of Natural Sciences, National University of Ireland Galway, Galway, Ireland.
Corrado SantocanaleCentre for Chromosome Biology, School of Natural Sciences, National University of Ireland Galway, Galway, Ireland.ORCID http://orcid.org/0000-0003-1337-5656
Afshin SamaliApoptosis Research Centre, School of Natural Sciences, National University of Ireland Galway, Galway, Ireland.ORCID http://orcid.org/0000-0002-8610-8375
John QuinnHematology, Beaumont Hospital, Dublin, Ireland.
Michael E O'DwyerApoptosis Research Centre, School of Natural Sciences, National University of Ireland Galway, Galway, Ireland.
Eva SzegezdiApoptosis Research Centre, School of Natural Sciences, National University of Ireland Galway, Galway, Ireland. eva.szegezdi@nuigalway.ie.ORCID http://orcid.org/0000-0002-5708-3535
Ollscoil na Gaillimhe – University of Galway · IEBeaumont Hospital · IE

Funding

Irish Cancer Society BCNI,14/ICS/B3042Science Foundation Ireland (SFI) 12/TIDA/B2388Science Foundation Ireland (SFI) BCNI,14/ICS/B3042
6 · The paper itself

Abstract

Acute myeloid leukaemia (AML) is an aggressive cancer with 50-75% of patients relapsing even after successful chemotherapy. The role of the bone marrow microenvironment (BMM) in protecting AML cells from chemotherapeutics and causing consequent relapse is increasingly recognised. However the role that the anti-apoptotic Bcl-2 proteins play as effectors of BMM-mediated drug resistance are less understood. Here we show that bone marrow mesenchymal stromal cells (BMSC) provide resistance to AML cells against BH

Indexed as

Drug Resistance, NeoplasmAntigens, CDbcl-X ProteinBiphenyl CompoundsBone MarrowCell Cycle ProteinsCell Line, TumorCyclin-Dependent Kinase 9CytarabineHumansLeukemia, Myeloid, AcuteMyeloid Cell Leukemia Sequence 1 ProteinNitrophenolsPiperazinesPiperidonesProtein Kinase InhibitorsABT-737Antigens, CDbcl-X ProteinBiphenyl CompoundsCDC7 protein, humanCDK9 protein, humanCell Cycle ProteinsCyclin-Dependent Kinase 9CytarabineMyeloid Cell Leukemia Sequence 1 ProteinNitrophenolsPHA 767491PiperazinesPiperidonesProtein Kinase InhibitorsProtein Serine-Threonine KinasesPyrrolesSulfonamides

Identifiers

PMID30361682
PMCPMC6202320
OpenAlexW2897466033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.